Visceral obesity and the role of the somatotropic axis in the development of metabolic complications

Johansson, 1994, High fibrinogen and plasminogen activator inhibitor activity in growth hormone-deficient adults, Arterioscler Thromb, 14, 434, 10.1161/01.ATV.14.3.434 Rosmond, 2000, The hypothalamic-pituitary-adrenal axis activity as a predictor of cardiovascular disease, type 2 diabetes and stroke, J Intern Med, 247, 188, 10.1046/j.1365-2796.2000.00603.x Boyko, 2000, Visceral adiposity and risk of type 2 diabetes a prospective study among Japanese Americans, Diabetes Care, 23, 465, 10.2337/diacare.23.4.465 Björntorp, 1993, Visceral obesity: a civilisation syndrome, Obes Res, 1, 206, 10.1002/j.1550-8528.1993.tb00614.x Bouchard, 1990, Basic and clinical aspects of regional fat distribution, Am J Clin Nutr, 52, 946, 10.1093/ajcn/52.5.946 Björntorp, 1996, Diabetes, 68 Cox, 1998, The development of cardiovascular disease in relation to anthropometric indices and hypertension in British adults, Int J Obes Relat Metab Disord, 22, 966, 10.1038/sj.ijo.0800705 Rosmond, 1998, Blood pressure in relation to obesity, insulin and the hypothalamic-pituitary-adrenal axis in Swedish men, J Hypertens, 16, 1721, 10.1097/00004872-199816120-00003 Pouliot, 1994, Waist circumference and abdominal sagittal diameter: best simple anthropometric indexes of abdominal visceral adipose tissue accumulation andrelated cardiovascular risk in men and women, Am J Cardiol, 73, 460, 10.1016/0002-9149(94)90676-9 Lean, 1995, Waist circumference as a measure for indicating need for weight management, BMJ, 311, 158, 10.1136/bmj.311.6998.158 Rexrode, 1998, Abdominal adiposity and coronary heart disease in women, JAMA, 280, 1843, 10.1001/jama.280.21.1843 Öhrvall, 2000, Sagittal abdominal diameter compared with other anthropometric measurements in relation to cardiovascular risk, Int J Obes Relat Metab Disord, 24, 497, 10.1038/sj.ijo.0801186 1999 Brummer, 1998, Effects of growth hormone treatment on visceral adipose tissue, Growth Horm IGF Res, 8, 19, 10.1016/S1096-6374(98)80021-X Han, 1997, Relationship between volumes and areas from single transverse scans of intra-abdominal fat measured by magnet resonance imaging, Int J Obes Relat Metab Disord, 21, 1161, 10.1038/sj.ijo.0800530 Abate, 1996, Insulin resistance and obesity, the role of fat distribution pattern, Diabetes Care, 19, 292, 10.2337/diacare.19.3.292 Kissebah, 1982, Relation of body fat distribution to metabolic complications of obesity, J Clin Endocrinol Metab, 54, 254, 10.1210/jcem-54-2-254 Kissebah, 1994, Regional adiposity and morbidity, Physiol Rev, 74, 761, 10.1152/physrev.1994.74.4.761 Scheen, 2000, From obesity to diabetes: why, when and who?, Acta Clin Belg, 55, 9, 10.1080/17843286.2000.11754266 Randle, 1963, The glucose fatty acid cycle: its role in insulin sensitivity and the metabolic disturbancies of diabetes mellitus, Lancet, I, 785, 10.1016/S0140-6736(63)91500-9 Sheehan, 2000, Metabolic complications of obesity. Pathophysiologic considerations, Med Clin North Am, 84, 363, 10.1016/S0025-7125(05)70226-1 Steppan, 2001, The hormone resistin links obesity to diabetes, Nature, 409, 307, 10.1038/35053000 Björntorp, 1995, Neuroendocrine abnormalities in human obesity, Metabolism, 44, 38, 10.1016/0026-0495(95)90208-2 Walker, 2001, Activation of the hypothalamic-pituitary-adrenal axis in obesity: cause or consequence?, Growth Horm IGF Res, 11, 91, 10.1016/S1096-6374(01)80015-0 Mårin, 1998, Androgens and abdominal obesity, Baillières Clin Endocrinol Metab, 12, 441, 10.1016/S0950-351X(98)80191-2 Björntorp, 1999, Perturbations of the hypothalamic-pituitary-adrenal axis and the metabolic syndrome in ageing, Growth Horm IGF Res, 9, 121, 10.1016/S1096-6374(99)80024-0 Björntorp, 2000, Hypertension and the metabolic syndrome: closely related central origin?, Blood Press, 9, 71, 10.1080/08037050050151762 Mårin, 1993, Androgen treatment of abdominally obese men, Obes Res, 1, 245, 10.1002/j.1550-8528.1993.tb00618.x Lobo, 2000, The importance of diagnosing the polycystic ovary syndrome, Ann Intern Med, 132, 989, 10.7326/0003-4819-132-12-200006200-00010 Iranmanesh, 1998, Unequal impact of age, percentage body fat, and serum testosterone concentrations on the somatotrophic, IGF-I, and IGF binding protein responses toa three-day intravenous growth hormone-releasing hormone pulsatile infusion in men, Eur J Endocrinol, 139, 59, 10.1530/eje.0.1390059 Johannsson, 1999, Is GH therapy indicated in the metabolic syndrome?, 264 Veldhuis, 1996, Physiological regulation of the human growth hormone (GH)-insulin-like growth factor type I (IGF-I) axis: predominant impact of age, obesity,gonadal function, and sleep, Sleep, 19, S221, 10.1093/sleep/19.suppl_10.S221 Veldhuis, 2001, Neurophysiological regulation and target-tissue impact of the pulsatile mode of growth hormone secretion in the human, Growth Horm IGF Res, 11, 25, 10.1016/S1096-6374(01)80005-8 Johannsson G, Mårin P, Johansson J-O, Bengtsson B-Å. Growthhormone and syndrome X. In: Smith RG, Thorner MO (eds.). Human growth hormone: research and clinical practice. Totowa, NJ: Humana Press: 247–260. Mårin, 1993, Low concentrations of insulin-like growth factor- in abdominal obesity, Int J Obes Relat Metab Disord, 17, 83 Nam, 1999, GH-binding protein in obese men with varying glucose tolerance: relationship to body fat distribution, insulin secretion and the GH-IGF-I axis, Eur J Endocrinol, 140, 159, 10.1530/eje.0.1400159 Johannsson, 1999, Growth hormone and the metabolic syndrome, J Endocrinol Invest, 22, 41 Johannsson, 2000, Growth hormone and ageing, Growth Horm IGF Res, 10, S25, 10.1016/S1096-6374(00)80006-4 Bengtsson, 1993, Treatment of adults with growth hormone (GH) deficiency with recombinant human GH, J Clin Endocrinol Metab, 76, 309, 10.1210/jc.76.2.309 Johannsson, 1997, Growth hormone treatment of abdominally obese men reduces abdominal fat mass, improves glucose and lipoprotein metabolism, and reduces diastolic blood pressure, J Clin Endocrinol Metab, 82, 727, 10.1210/jc.82.3.727 Howard, 1996, A receptor in pituitary and hypothalamus that functions in growth hormone release, Science, 273, 974, 10.1126/science.273.5277.974 Guillaume, 1994, Growth hormone (GH)-releasing hormone secretion is stimulated by a new GH-releasing hexapeptide in sheep, Endocrinology, 135, 1073, 10.1210/en.135.3.1073 Lieber, 1997, Growth hormone secretagogues increases muscle strength during remobilization after canine hindlimb immobilization, J Orthop Res, 15, 519, 10.1002/jor.1100150407 Laron, 1995, Intranasal administration of the GHRP hexarelin accelerates growth in short children, Clin Endocrinol (Oxf), 43, 631, 10.1111/j.1365-2265.1995.tb02929.x Svensson, 1998, Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energyexpenditure, J Clin Endocrinol Metab, 83, 362, 10.1210/jc.83.2.362 James, 1996, The epidemiology of obesity, 1 Narbro, 1999, Sick leave and disability pension before and after treatment for obesity: a report from the Swedish Obese Subjects (SOS) study, Int J Obes Relat Metab Disord, 23, 619, 10.1038/sj.ijo.0800890